Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment.
Gane EJ, Metivier S, Nahass R, Ryan M, Stedman CA, Svarovskaia ES, Mo H, Doehle B, Dvory-Sobol H, Hedskog C, Lin M, Brainard DM, Yang JC, McHutchison JG, Sulkowski M, Younes Z, Lawitz E. Gane EJ, et al. Among authors: doehle b. Hepatol Commun. 2017 Jun 22;1(6):538-549. doi: 10.1002/hep4.1060. eCollection 2017 Aug. Hepatol Commun. 2017. PMID: 29404477 Free PMC article.
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S. Hezode C, et al. Among authors: doehle bp. J Hepatol. 2018 May;68(5):895-903. doi: 10.1016/j.jhep.2017.11.032. Epub 2017 Dec 6. J Hepatol. 2018. PMID: 29221887 Clinical Trial.
L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.
Svarovskaia ES, Gane E, Dvory-Sobol H, Martin R, Doehle B, Hedskog C, Jacobson IM, Nelson DR, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H. Svarovskaia ES, et al. Among authors: doehle b. J Infect Dis. 2016 Apr 15;213(8):1240-7. doi: 10.1093/infdis/jiv564. Epub 2015 Nov 24. J Infect Dis. 2016. PMID: 26603202 Free PMC article.
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.
Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, Svarovskaia E, Dvory-Sobol H, Doehle B, Hedskog C, Yun C, Brainard DM, Knox S, McHutchison JG, Miller MD, Mo H, Chuang WL, Jacobson I, Dore GJ, Sulkowski M. Zeuzem S, et al. Among authors: doehle b. J Hepatol. 2017 May;66(5):910-918. doi: 10.1016/j.jhep.2017.01.007. Epub 2017 Jan 18. J Hepatol. 2017. PMID: 28108232 Free article.
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Pang PS, Chuang SM, Ma J, Ding X, Afdhal NH, Kowdley KV, Gane EJ, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H. Sarrazin C, et al. Gastroenterology. 2016 Sep;151(3):501-512.e1. doi: 10.1053/j.gastro.2016.06.002. Epub 2016 Jun 11. Gastroenterology. 2016. PMID: 27296509 Clinical Trial.
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Sarrazin C, Cooper CL, Manns MP, Reddy KR, Kowdley KV, Roberts SK, Dvory-Sobol H, Svarovskia E, Martin R, Camus G, Doehle BP, Stamm LM, Hyland RH, Brainard DM, Mo H, Gordon SC, Bourliere M, Zeuzem S, Flamm SL. Sarrazin C, et al. Among authors: doehle bp. J Hepatol. 2018 Dec;69(6):1221-1230. doi: 10.1016/j.jhep.2018.07.023. Epub 2018 Aug 9. J Hepatol. 2018. PMID: 30098373 Clinical Trial.
44 results